10 3. 10 4. 10 5. 19. 2. 78. F. G. PT. AGM. CD8+ Lymph node. PT. AGM. CD8+ PBMCs. 0. 1000 10000 1x105. CD45RA. 0. 1000. 10000. 1x105 37.6. 43.3. 4.48.
1971-1972 n = 4,498. Stage III. 1977-1979 n = 4,190. Stage IV. 1981-1984 n = 3,204. Stage V. 1987-1991 n = 2,446. Reykjavik Study cohort. 18,912 participants.
A. B. Ips-1+/- WT Lp. Ips-1-1- WT Lp. B6 WT Lp. Mda5-- WT Lp. 2 - 0. RLU. RLU. 0.01. 0.01. 0.001. 0.001. 0.0001. 0.0001 o 24 48 72. O 24 48 72. O. Ips-1+/- Adot.
HOMO SAPIENS HER3 (ERBB3) SFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYN 124. HOMO SAPIENS ERBB4.
G LTRA SMT | FLITY WK DVTK MKP FDL - SG FP G V | SGP LSIFNNNII ... T L F GVA SVT N H I SE I FAY F FS FK LIRQ | G H VKV LCM G L GGNV LR FLY | SW.
a) Overlap in genes differentially regulated versus control in CSE-treated and ... 17/127. -1.78. Focal adhesion. 19/202. -1.77. Metabolic pathways. 66/1239.